Results 251 to 260 of about 8,253,745 (359)

Crucial parameters for precise copy number variation detection in formalin‐fixed paraffin‐embedded solid cancer samples

open access: yesMolecular Oncology, EarlyView.
This study shows that copy number variations (CNVs) can be reliably detected in formalin‐fixed paraffin‐embedded (FFPE) solid cancer samples using ultra‐low‐pass whole‐genome sequencing, provided that key (pre)‐analytical parameters are optimized.
Hanne Goris   +10 more
wiley   +1 more source

Case reports in the past, present and future

open access: yesEuropean Journal of Case Reports in Internal Medicine
John G. Kellett
doaj   +1 more source

Diversity Presents in Issue Two

open access: yesJACC: Case Reports, 2019
Julia Grapsa, MD, PhD
doaj   +1 more source

Mesenteric Castleman disease: Two case reports and review of literature. [PDF]

open access: yesWorld J Gastrointest Surg
Jizhi SN   +5 more
europepmc   +1 more source

Phenotypic and genotypic characterization of single circulating tumor cells in the follow‐up of high‐grade serous ovarian cancer

open access: yesMolecular Oncology, EarlyView.
Single circulating tumor cells (sCTCs) from high‐grade serous ovarian cancer patients were enriched, imaged, and genomically profiled using WGA and NGS at different time points during treatment. sCTCs revealed enrichment of alterations in Chromosomes 2, 7, and 12 as well as persistent or emerging oncogenic CNAs, supporting sCTC identity.
Carolin Salmon   +9 more
wiley   +1 more source

Vision for JACC: Case Reports

open access: yesJACC: Case Reports, 2019
Julia Grapsa, MD, PhD
doaj   +1 more source

CARE-DN: An Extension of the CARE Guidelines for Dry Needling Case Reports. [PDF]

open access: yesCureus
Tzigkounakis G   +13 more
europepmc   +1 more source

Combining antibody conjugates with cytotoxic and immune‐stimulating payloads maximizes anti‐cancer activity

open access: yesMolecular Oncology, EarlyView.
Methods to improve antibody–drug conjugate (ADC) treatment durability in cancer therapy are needed. We utilized ADCs and immune‐stimulating antibody conjugates (ISACs), which are made from two non‐competitive antibodies, to enhance the entry of toxic payloads into cancer cells and deliver immunostimulatory agents into immune cells.
Tiexin Wang   +3 more
wiley   +1 more source

Voices in Cardiology

open access: yesJACC: Case Reports, 2019
Julia Grapsa, MD, PhD
doaj   +1 more source

Home - About - Disclaimer - Privacy